Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.
Department of Medicine, University of Alberta, Edmonton, Alta. richard.long@ualberta.ca
Richard
R
Long
Michael
M
Gardam
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D008403:Mass Screening; D009169:Mycobacterium tuberculosis / Q000254:growth & development*; D018124:Receptors, Tumor Necrosis Factor; D012008:Recurrence; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000382:microbiology* / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept